Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

2.
3.

Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.

Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A; ALERT Study Group. Assessment of Lescol in Renal Transplantation.

J Cardiovasc Risk. 2001 Apr;8(2):63-71.

PMID:
11324372
4.

Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.

Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.

Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.

PMID:
18343245
5.
7.

Impact of fluvastatin on hyperlipidemia after renal transplantation.

Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.

Transplant Proc. 2004 Sep;36(7):2141-4.

PMID:
15518777
8.

Fluvastatin titrate-to-goal clinical practice study.

Weiss RJ.

Am J Ther. 1998 Sep;5(5):281-5.

PMID:
10099070
9.

Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial.

Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Veldhuisen DJ; Folic Acid on Risk Diminishment After Acute Myocarial Infarction Study Group.

Int J Cardiol. 2004 Feb;93(2-3):175-9.

PMID:
14975544
10.

[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].

Ceska R.

Vnitr Lek. 1996 Aug;42(8):533-6. Czech.

PMID:
8967021
11.

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Olsson AG, Pauciullo P, Soska V, Luley C, Pieters RE, Broda G, Palacios B; Fluvastatin Study Group.

Clin Ther. 2001 Jan;23(1):45-61.

PMID:
11219479
12.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
13.

Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.

Martínez-Castelao A, Grinyó JM, Fiol C, Castiñeiras MJ, Hurtado I, Gil-Vernet S, Serón D, Porta I, Miñarro A, Villarroya A, Alsina J.

Kidney Int Suppl. 1999 Jul;71:S231-4.

PMID:
10412785
14.

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT.

Clin Ther. 2001 Feb;23(2):177-92.

PMID:
11293552
16.

[Effect of fluvastatin on serum lipid levels in essential hypertension].

Járai Z, Kapocsi J, Farsang C, Detki K, Pados G, Sebestyén Z, Holló J.

Orv Hetil. 1996 Aug 25;137(34):1857-9. Hungarian.

PMID:
8927338
17.

Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients.

Bruckert E, Lièvre M, Giral P, Crepaldi G, Masana L, Vrolix M, Leitersdorf E, Dejager S.

Am J Geriatr Cardiol. 2003 Jul-Aug;12(4):225-31.

PMID:
12888702
18.
19.

Supplemental Content

Support Center